Structural analysis and insertion study reveal the ideal sites for surface displaying foreign peptides on a betanodavirus-like particle

Junfeng Xie1†, Kunpeng Li1†, Yuanzhu Gao1†, Runqing Huang1, Yuxiong Lai2, Yan Shi1, Shaowei Yang1, Guohua Zhu1†, Qinfen Zhang1* and Jianguo He1,3*

Abstract
Betanodavirus infection causes fatal disease of viral nervous necrosis in many cultured marine and freshwater fish worldwide and the virus-like particles (VLP) are effective vaccines against betanodavirus. But vaccine and viral vector designs of betanodavirus VLP based on their structures remain lacking. Here, the three-dimensional structure of orange-spotted grouper nervous necrosis virus (OGNNV) VLP (RBS) at 3.9 Å reveals the organization of capsid proteins (CP). Based on the structural results, seven putative important sites were selected to genetically insert a 6× histidine (His)-tag for VLP formation screen, resulting in four His-tagged VLP (HV) at positions N-terminus, Ala220, Pro292 and C-terminus. The His-tags of N-terminal HV (NHV) were concealed inside virions while those of 220HV and C-terminal HV (CHV) were displayed at the outer surface. NHV, 220HV and CHV maintained the same cell entry ability as RBS in the Asian sea bass (SB) cell line, indicating that their similar surface structures can be recognized by the cellular entry receptor(s). For application of vaccine design, chromatography-purified CHV could provoke NNV-specific antibody responses as strong as those of RBS in a sea bass immunization assay. Furthermore, in carrying capacity assays, N-terminus and Ala220 can only carry short peptides and C-terminus can even accommodate large protein such as GFP to generate fluorescent VLP (CGV). For application of a viral vector, CGV could be real-time visualized to enter SB cells in invasion study. All the results confirmed that the C-terminus of CP is a suitable site to accommodate foreign peptides for vaccine design and viral vector development.

Introduction
Piscine nodaviruses, the causal agents of viral nervous necrosis (VNN) or viral encephalopathy and retinopathy (VER), are members of the Betanodavirus Nodaviridae family. Betanodaviruses are small, spherical, non-enveloped viruses with a bipartite single-stranded (+) RNA genome encapsulated by 180 molecules of a single self-assembly capsid protein (CP) [1]. They are important viruses in aquaculture because they can infect more than 40 marine fish species [2], especially high-value fish species, primarily at the larval and juvenile stages [3], which results in mass mortality and serious economic losses. To effectively control the disease, vaccine against betanodavirus is a pivotal strategy with general acceptance. Several types of vaccines have been reported, including poorly protective vaccines constituting recombinant CP [4, 5] or synthetic peptides derived from CP [6] as well as effective vaccines containing inactive betanodaviruses [7–9] or virus-like particles (VLP) [10–12]. VLP are well-structured particles with high similarity to native virions and they can assemble spontaneously from single (i.e. betanodavirus CP) or multiple structural proteins under specific conditions [13, 14]. VLP can be produced either

*Correspondence: lsszqf@mail.sysu.edu.cn; lsshjg@mail.sysu.edu.cn
†Junfeng Xie, Kunpeng Li and Yuanzhu Gao authors contributed equally.
1State Key Laboratory of Biocontrol, MOE Key Laboratory of Aquatic Product Safety, Institute of Aquatic Economic Animals and Guangdong Province Key Laboratory for Aquatic Economic Animals, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China
Full list of author information is available at the end of the article

© 2016 Xie et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
eukaryotically or prokaryotically, and prokaryotic VLP production, in particular, presents advantages of high production, short duration, low cost, and easy manipulation. Theoretically, VLP are not infectious and they are safer than attenuated vaccines because of not containing viral genomes. Therefore, VLP is one of the most promising models for vaccine research and virology study.

Structural information of VLP is important in aiding vaccine design, modification or remodeling to develop the viral carriers (antigens or nucleic acids carrying vectors) with surface display techniques [15], to exploit multivalent vaccines [16], to manipulate the tropism of infection [17], and to achieve easy purification during vaccine production [18]. Cryo-Electron microscopy (cryo-EM) that allows visualization of macromolecules in their native state has been used to obtain the structural information of many virus particles. Combined with techniques of three-dimensional (3D) reconstruction, cryo-EM images of macromolecules can be used to study the high-resolution structure and interactions of macromolecules, helping to reveal the functions of assembly and invasion machineries of viral capsids. Several atomic resolution structures of virus (or VLP) and protein complexes have recently been reported [19, 20].

The OGNNV VLP was successfully produced prokaryotically and proved to be an effective vaccine against OGNNV [12]. In the present study, we want to verify the possibility of modification of betanodavirus VLP to achieve the purposes of vaccine research and viral vector development. Firstly, the 3D structure of native OGNNV VLP (RBS) at 3.9 Å resolution was determined. Not only the secondary structures but also some side-chain density were well defined and allowed us to identify the putative important sites for accommodating foreign peptides. Secondly, based on structural information, 6× histidine (His) tag and green fluorescent protein (GFP) were inserted into different positions by genetic approach to reveal the functions of assembly and the carrying capacities of the sites of modified VLP were also verified. Finally, the potential applications of easily purified vaccines and viral carriers inserted at the C-terminal site were tested. Our results prove betanodavirus VLP can be modified by insertion and suggest the key sites for accommodating foreign peptides for the purpose of vaccine research and viral vector development.

Materials and methods

VLP production and purification

Full length cp gene of OGNNV (GenBank: AF534998) was cloned into modified pQE30 (Qiagen) and expressed prokaryotically in M15 Escherichia coli as described [12]. VLP were produced as follows. A volume of 80 mL seed culture grown overnight at 37 °C was inoculated equally into 8 flasks of 1 L LB-broth medium supplemented with 100 μg/mL ampicillin. When the cell density reached an OD600 of 0.3–0.4, the culture was cooled down to 30 °C and 0.9 mM IPTG was added for induction. After induction for 2 h at 30 °C, cells were harvested by centrifugation (5000 × g, 4 °C, 20 min), resuspended in 100 mL lysis buffer (pH 8.0 PBS with 1% Triton X-100 and 2 mM PMSF), lysed by sonication and centrifuged at 40 000 × g for 20 min. The whole cell pellets, supernatants and cell debris were saved for SDS-PAGE for a solubility test. Collected supernatant was ultracentrifuged at 250 000 × g (Beckman Optima L-100XP) for 1 h against a 30% sucrose cushion. The pellet was resuspended in 4 mL of PBS (pH 8.0) and further purified using a 10–40% (w/w) sucrose gradient and ultracentrifuged at 250 000 × g for 3 h. Fractions of various buoyancies were collected and examined by SDS-PAGE and immunoblotting. The shape, size and integrity of the VLP were confirmed by the negative staining and transmission electron microscope (TEM) (JEOL JEM-1400) observation. The fractions containing fine structured and highly pure VLP were diluted with PBS and ultracentrifuged at 250 000 × g for 1 h to remove the sucrose. The pellets were resuspended with PBS and the VLP (RBS or the modified VLP) were verified again by TEM. RBS was stored for the 3D structure research. Purified VLP were applied to SDS-PAGE and BCA Protein Assay Kit (Thermo) to determine the concentration and stored at −80 °C until use.

Cryo-EM imaging, 3D reconstruction and model building

A 3.5 μL aliquot of the RBS sample was applied to a JG holey grid and blotted for 3 s in a chamber at 100% humidity and flash frozen using an FEI Vitrobot Mark IV. Particles were imaged with an FEI 300 KvitroTitan Krios cryo-electron microscope equipped with a Gatan UltraScan4000 16-megapixel CCD at nominal magnification of 96 000×, corresponding to a final pixel size of 0.933 Å. The total dose was approximately 20 e−/Å2. The defocus values ranged from −1.0 to −3.0 μm.

Particles were picked up from the micrographs using the e2boxer.py program in EMAN2 [21] and the contrast transfer function parameters were determined using EMAN1.9 [22]. Article images (32 000) from 1359 frames were used in the final reconstruction. The data were randomly separated into two independent groups and JSPR was used to refine the center, orientation, defocus, astigmatism, and magnification of each particle and rebuild the final density map [23]. The resulting density maps were sharpened by applying the B-factor using the proc3d in EMAN1.9 [22]. The resolution was assessed using the gold-standard by the 0.143 FSC criterion [24]. The local resolution was also calculated using the two independent
reconstructions from halves of the total particles by ResMap [25].

All the protein subunit segmentation and visualizations were finished using UCSF Chimera [26]. The CP sequence was used to build a comparative model by Phyre2 [27]. The model was then fitted into the density map using the “fit into map” module in UCSF Chimera [26] according to the previously reported methods [28]. Further refinement and optimization was done by the Coot [29] and Phenix [30]. Finally, we used the refined model instead of the initial comparative model to guide the segmentation of its corresponding density.

**Plasmid construction**

Primers NHV-L and CP-R or RBS-L and CHV-R were used to amplify the cp gene from cDNA of RNA2 and the product was then inserted into pQE30 (Qiagen) using SacI and HindIII or EcoRI and HindIII sites to generate pQE-His-CP or pQE-CP-His, respectively. These plasmids are transformed into M15 220GFPCP and pR-CPGFP. All of these plasmids were named as pR-GFPCP, pR-CPGFP,HV, and pR-CPGFP,III or pR-CPGFP,III and pR-CPGFP,IV to determine the location of virions.

**VLP invasion assay**

The invasion assays were performed using RBS, HV and CGV on OGNNV-sensitive Asian sea bass (*Lates calcarifer*) fibroblast (SB) cells as previous described [12]. In brief, SB cells were grown on coverslip at 26 °C. VLP (0.3 μg/μL) diluted in minimal essential medium (Gibco) were incubated with SB cells at 0 °C for 1 h for attachment and invasion synchronization. After being thoroughly washed with PBS to remove excessive VLP, SB cells were received fresh medium and were switched to 26 °C to trigger invasion for 1.5 h. For observation of CGV in real-time, fluorescent microscopy was performed at the indicated time. For indirect immunofluorescence assays (IFA) [31], media were removed and cells were fixed with 4% paraformaldehyde for 30 min and then permeabilized for 5 min in 0.2% PBS-Triton X-100 (vol/vol) at room temperature. The cells were washed with 0.05% PBST (all wash steps below indicate three times of 0.05% PBST) receive fresh medium and were switched to 26 °C to trigger invasion for 1.5 h. For observation of CGV in real-time, fluorescent microscopy was performed at the indicated time. For indirect immunofluorescence assays (IFA) [31], media were removed and cells were fixed with 4% paraformaldehyde for 30 min and then permeabilized for 5 min in 0.2% PBS-Triton X-100 (vol/vol) at room temperature. The cells were washed with 0.05% PBST (all wash steps below indicate three times of 0.05% PBST) and blocked with 5% FBS. IFA was performed at room temperature by incubating cells for 1 h with mouse anti-His monoclonal antibody (EarthOx, USA) at 500-fold dilution or mouse anti-VLP sera (polyclonal antibody produced in-house, total immunoglobulin) at 200-fold dilution. After that, grids were incubated for 1 h with goat anti-mouse IgG conjugated to 5 nm gold particles (Sigma) at 50-fold dilution. All incubations were performed at room temperature and grids were washed 3 times with 0.05% PBS-Tween 20 (vol/vol, PBST) between each step from the blocking step. VLP and gold particles were confirmed by negative staining and TEM observation.

**Affinity chromatography of HV**

As described above for VLP production, cells expressing HV were induced, harvested, resuspended and sonicated in lysis buffer with addition of 10 mM imidazole.

**Immuno-EM**

RBS or HV were applied onto carbon-filmed grids, left for 15 min, and blotted until nearly dry. Grids were then blocked by incubation face down on drops of 2% bovine serum albumin (BSA) for 30 min. Grids were incubated for 1 h with mouse anti-His monoclonal antibody (EarthOx, USA) at 100-fold dilution or mouse anti-VLP sera (polyclonal antibody produced in-house, total immunoglobulin) at 200-fold dilution. After that, grids were incubated for 1 h with goat anti-mouse IgG conjugated to 5 nm gold particles (Sigma) at 50-fold dilution. All incubations were performed at room temperature and grids were washed 3 times with 0.05% PBS-Tween 20 (vol/vol, PBST) between each step from the blocking step. VLP and gold particles were confirmed by negative staining and TEM observation.
After centrifugation, a one bed volume of the collected supernatant was mixed with a half bed volume of nickel-nitrilotriacetic acid (Ni–NTA) matrices (Qiagen) that had been previously washed three times with lysis buffer for 2 h at 4 °C with rotation. The matrices were then washed six times with three bed volume of wash buffer (lysis buffer with addition of 26 mM imidazole) with 15 min rotation during each wash. Proteins bound to the matrices were eluted with a one bed volume of elution buffer (lysis buffer with addition of 250 mM imidazole) for 30 min at 4 °C with rotation. The eluted proteins were concentrated and the buffer was exchanged with PBS using Amicon® Ultra Centrifugal Filters (Merck Millipore) according to the manufacturer’s instructions. Purified HV were subjected to SDS-PAGE and BCA protein assay kit (Thermo) for concentration determination, and to EM for structural completeness evaluation. Purified HV were stored at −80 °C until use.

Sea bass immunization and antibody response detection
Healthy Asian sea bass juveniles with an average body weight of 5 g were maintained in flow-through freshwater at room temperature, aerated with an air pump and acclimated to the system for 3 days, at which time tissues were collected from 6 random fish for virus-free test and as control samples before injection (0 h). Feeding was suspended 12 h before vaccination and sampling. Sea bass were divided equally into ten groups with 40 fish per group. Two independent trials were conducted to determine the impact of immunization times (once and twice) to the vaccination efficiency and a 1-week interval was set before the booster. RBS or CHV were injected intra-muscularly at doses of 15, 25, 40, 60 and 80 μg/g fish body weight (FBW) as high concentration groups (V.H.: high concentration RBS; H.H.: high concentration CHV) or 1.5, 2.5, 3.5, 5.5 and 6.5 μg/g FBW as low concentration groups (V.L.: low concentration RBS, H.L. low concentration CHV) into the dorsum of anesthetized sea bass. PBS was also injected as negative controls. For antibody detection, thirty fish from each group in each trial were randomly selected. At indicated sampling time points (every week) post-immunization, fish sera were collected from the caudal vein and combined as one sample. Antibody titers of anti-VLP sera were determined by antigen-capture ELISA. All the experimental protocols concerning the handling of fish were in accordance with the requirements of the Institutional Animal Care and Use Committee of Sun Yat-sen University, P. R. China.

Antigen-capture ELISA
Antigen-capture ELISA was performed as described [12] to determine the antibody titers of anti-VLP sera. In brief, 50 μL of diluted fish sera (1:100) were coated in a well of 96-well microtiter plate at 4 °C overnight. The plate was conducted to room temperature and washed three times with 200 μL PBS. After blocking with 5% BSA in PBS for 1 h and washing three times with 1% PBST (all wash steps below indicated three times of 200 μL 1% PBST), 1 ng VLP was added to each well and incubated for 1 h. After wash, the plate was incubated with in-house produced mouse anti-VLP antiserum at a dilution of 1:1000 in PBST for 1 h. The plate was washed and peroxidase-conjugated goat anti-mouse IgG (Sigma) at a dilution of 1:3000 was added and incubated for 1 h. Following thorough washes (five times), 100 μL of OPD substrate (Sigma) was added and the color development was conducted at room temperature. The reaction was stopped by the addition of 4 M sulfuric acid and the absorbance at 492 nm was determined. Statistical differences of titers from different groups were assessed by paired Student’s t tests. Numerical results are presented as mean ± standard deviation with 95% confidence intervals and p < 0.05 was considered statistically significant.

Results
The features of RBS capsid
Final density map of the RBS capsid reconstructed by JSPR was estimated at 3.9 Å based on the “gold” standard FSC = 0.143 criterion (Additional file 2) (EMDB 6453). The 3D structure of RBS (Figures 1A and B) reveals that RBS has a capsid with 30 nm in diameter with T = 3 icosahedral symmetry (Additional file 3). Outside of the surface of the capsid, there are 60 protrusions located at the top of the center of each asymmetry unit, and with the protrusions, the diameter of the whole RBS enlarges to be around 38 nm (Figure 1C). There are three chemical identical subunits with slight conformational variations in the spatial location, VPa, VPb and V Pc, in each asymmetric unit (Figures 1D and E) (also see Additional file 4). At current resolution, the alpha helix and beta sheets could be clearly identified, and most β-strands in the capsid were already separated (Figures 1D and E). Some distinctive side chains on helices, β-strands and loops could be identified (Figure 1F). Inside the capsid, there are some densities which belong to the randomly packaged RNA (Additional file 3). It was difficult to figure out the pattern of the RNA and the density became much weaker as the resolution was improved, because the reconstruction imposes icosahedral symmetry while the RNA should not be in the same symmetry.
A model for the capsid protein was built (PDB 3JB M) based on the density map at current resolution. Five VPa contribute to the densities around five-fold axis. VPb and VPc compose the densities of the hexagons together.
could only identify the densities of residues 52–220 of VPa and VPb. While for VPc, we could detect the densities of 17 more amino acid residues at the N-terminal (Figures 1D and E). These 17 amino acids compose a loop from the two-fold axis and cross the VPb (Figure 1), then form a trident structure with another two N-terminals of the VPc at the three fold (Additional file 5).

Based on the density map and the model of the capsid, both N-terminals of the VPa, VPb and VPc are inside the capsid. If we low-pass the density map to 8 Å, three linker densities (residues 210–220) from each subunit of the asymmetry unit could be demonstrated connecting capsid shell to the protrusions at residues 220. There is no doubt that the protrusions densities belong to the residues 220–338, the C-terminus of the capsid protein. Accordingly, we separate CP into three independent domains: the N-terminal domain (N domain) (residues 1–50), the Shell domain (S domain) (residues 51–220) and the Protrusion domain (P domain) (221–338). The S domain is mainly composed of a canonical jelly-roll, and a β-barrel fold containing eight antiparallel β-strands. The S domain by itself forms a continuous capsid shell without any notable holes.

The flexible protrusions and the putative sites for insertion study

Three P domains of VPa, b and c composed a trimeric protrusion in each asymmetry unit. Between S and P domains, there is a high flexible linker loop composed of residues 210–220 functioning as a connection (Figure 1C). The flexible linker loops are responsible for the spatial variation of the protrusions.

Our map demonstrates that the spatial variable protrusions outside the capsid are at relative low resolution. Local resolution analyses by ResMap show that the resolution of protrusion density is even worse than 10 Å (Additional file 6), resulting in no structural details of the protrusions being identified. Although protrusions have a low resolution, the structure we obtained allows identifying some residues for putative sites for VLP modification. Furthermore, the fine structure of capsid shell indicates that the insertion may influence the organization of VLP. Therefore, the modification study was focused on the protrusions and linker loops in order to display the foreign peptide. As a negative site for the virion surface displaying, the N-terminals are located inside the capsid shell. Consequently, residues 0 (N-terminus), 220, 254,
286, 292, 301, and 338 (C-terminus) of CP were selected as potential targets for subsequent insertion study.

**Modified VLP production**

Based on the structure and model, we inserted a 6 × His-tag into seven different positions of CP connected with flexible peptides as indicated in Figure 2A. All HCP were subjected to SDS-PAGE and immunoblotting to verify their expression and solubility after prokaryotic expression, sonication, and centrifugation (Figure 2). All of the HCP were correctly expressed after optimization except for 286HCP, which was expressed in very small quantities. However, the soluble forms of 292HCP and 301HCP were far less than those of other HCP (Additional file 7). Accordingly, the sequence of amino acid residues around positions Ala286, Pro292, and Trp301 were essential for CP expression and solubility. After sucrose gradient ultracentrifuge purification of the supernatants, we got tagged VLP of N-terminal HV (NHV), 220HV, 292HV, and C-terminal HV (CHV) (Figure 2B). Surprisingly, the highly expressed and soluble 254HCP is maintained as a monomer and cannot form VLP, suggesting that the position 254 of CP is important for VLP formation. Although different HV with shapes similar to that of RBS were produced, their quantities were remarkably different, as shown in Figure 2C. Comparing with the production of RBS (100%), the final quantities of NHV or CHV in the same culture volume were 89 ± 12.7% or 96 ± 13.3% while the amount of 220HV was 124 ± 13.2% and that of 292HV was less than 8% of RBS. 301HCP was unable to form sufficient amounts of particles (301HV, data not shown) for standard gradient ultracentrifugation, estimating that the production of 301HV was less than 1% of the RBS production. Furthermore, the broken particles were more frequently seen in 292HV and 301HV than in NHV, 220HV, and CHV. These results suggest that the internally inserted His-tag may influence the formation of highly structured particles while the insertions at N-/C-termini and linker loop were less affected. These results were consistent with the structural analysis, because the N-/C-termini and the linker loop are located far from the interaction domains and functional sites. Therefore, NHV, 220HV, and CHV were selected for further study because of their higher yields.

**Surface display of His-tag on HV verified by immuno-EM**

Immuno-EM assays of purified HV were performed to determine whether or not the His-tag presents at the surface of HV. The mouse anti-His antibodies and gold-labeled goat anti-mouse antibodies were used to detect surface displaying His-tags on fine structured VLP. As shown in Figure 3A, gold particles could be seen clearly around the 220HV and CHV but not be presented in the marginal places without VLP. This finding demonstrates that the His-tag is displayed on the surface of 220HV and CHV. NHV cannot be labeled with gold particles, which is similar to the negative control (RBS), suggesting that the N-terminal His-tag is not exposed outside of NHV. Structural information indicates that the trend of the N-terminal His-tag should be partially linked to the enclosed nucleic acid, which corresponds to the immune-EM results. By contrast, all types of VLP could be labeled with gold particles using polyclonal anti-VLP antisera (Figure 3B). These results indicate that the displayed His-tags do not affect the binding of anti-VLP antibodies.

**Cell entry ability of HV**

VLP invasion assays were performed to verify the entry process of HV and determine whether or not the displayed His-tags alter the surface structure of HV. Theoretically, the same entry process and comparative entry
ability should be observed in the entry assays of HV and RBS if the surface structures of these particles are similar. In the assays, SB cells were incubated with HV, and RBS served as the positive control. The particles that had successfully entered were visualized by IFA. NHV, 220HV and CHV can enter SB cells via a pattern similar to that of RBS, as detected by IFA using anti-VLP antibody (left column of Figure 4). The particle entry was completed within 1.5 h and the particles aggregated next to or around the cell nuclei, indicating rapid endocytosis and they accumulate in some endosome-like compartments. These results demonstrate identical entry abilities between HV and RBS. Furthermore, the His-tags of 220HV and CHV could be detected by anti-His antibodies whereas the His-tag of NHV could not be labeled (right column of Figure 4). These findings were in accordance with the results of immune-EM. The invasion assays demonstrate that both native VLP (RBS) and modified VLP (HV) can specifically bind to the virus entry receptor(s) on the cell membrane and enter SB cells via the same endocytic pathway. Thus, the outer shell of HV is structurally indistinguishable from that of RBS or native virus, and the His-tags do not change the cell tropism of HV. By detecting the His-tags, HV and native VLP or viruses can be easily distinguished by immunoassay. Moreover, the key sites, such as Ala220 in the linker loop and C-terminus of CP, are excellent positions for accommodating foreign peptides on the outer surface of virions, exhibiting the potential application for viral vectors.

Chromatographic purification of HV

As an application of vaccine design for tagged VLP, we decided to test the purification function of His-tag by affinity chromatography because the tags are present on the surface of 220HV and CHV. Bacteria expressing RBS, 220HV, and CHV were harvested and broken by sonication. After centrifugation, the supernatants were purified by Ni-NTA beads and the purification results are shown in Figure 5. As an alternative method for VLP purification, affinity chromatography was used to purify 220HV and CHV, as detected by SDS-PAGE and immunoblotting (Figure 5A). Moreover, the purified products maintained

![Figure 3 Immuno-EM of different kinds of VLP.](image-url)  

**Figure 3 Immuno-EM of different kinds of VLP.** RBS, NHV, 220HV, and CHV were immune-labeled with gold particles using mouse anti-his antibodies (A) or mouse anti-VLP sera (B) as the first antibody as indicated. The black dots are the 5 nm gold particles conjugated with goat anti-mouse secondary antibodies and the bars indicate 100 nm.

![Figure 4 HV maintained the cell entry ability.](image-url)  

**Figure 4 HV maintained the cell entry ability.** The purified RBS and three types of HV were used to perform cell invasion assays. After 1.5 h incubation, the cells were fixed and IFA were performed using anti-His antibodies (left panels) and anti-VLP sera (right panels). The VLP in cells were labeled in green and the cell nuclei were counterstained in red. The His-tags of HV were stained positively when they were presented at the surface of the virions. The bar indicates 25 µm.
Without the His-tag, RBS could not be enriched during purification. Moreover, the resulting quantities of 220HV and CHV produced from 1 L cell culture volume were 3.63±0.55 and 3.84±0.46 mg/L, respectively.Apparently, CHV was more effective than 220HV in affinity chromatography because the production quantities of 220HV were 29% more than those of CHV when using the ultracentrifugation method. This result suggests that the His-tags presented on the C-terminus are more successful than those displayed on Ala220 of the linker loop. The chromatography-purified HV can be used directly as vaccine although the concentration is lower than that obtained by ultracentrifugation. All the purification procedures were completed within 4 h, which means the present approach was much faster than the ultracentrifugation method. In a word, we successfully purified HV using a one-step affinity chromatography in a time- and effort-saving way.

The immunogenicity of CHV
Chromatography-purified CHV was used as a vaccine to immunize sea bass juveniles to test the immunogenicity of CHV. The juveniles were vaccinated once or twice by intramuscular injection at doses of 15 μg/g FBW (H.H. group) and 1.5 μg/g FBW (H.L. group). RBS was used as the positive vaccine at the same concentrations (V.H. group and V.L. group) for comparison, and PBS served as the negative control. Fish sera from vaccinated and control sea bass were collected every week, and the NNV-specific antibody response was determined by antigen-capture ELISA. Figure 6A shows that both H.H. and V.H. stimulated levels of NNV-specific antibodies, being significantly higher than those of the PBS control ($p < 0.01$) when the fish were immunized once. The antibody response induced by CHV was nearly identical to that induced by RBS ($p > 0.05$), and the highest antibody titer was obtained at around 5 or 6 weeks post-immunization. Although H.L. or V.L. stimulated levels of antibody responses to a higher level than those induced by the PBS control ($p < 0.01$), their average antibody titers (0.81 U for H.L. or 0.66 U for V.L.) were threefold lower than those of H.H. (2.39 U) or V.H. (2.55 U). Therefore, immunization was performed twice to enhance the antibody response. As shown in Figure 6B, two injections of H.H. and V.H. stimulated very high levels of antibodies with average titers of 6.49 and 6.1 U, which were two-fold higher than those obtained in H.H. or V.H. with one immunization. The high antibody titers induced by H.H. or V.H. remained stable for 10 weeks. Two injections of H.L. or V.L. improved the average antibody titers...
by two- to threefold compared with one immunization, although their titers were far lower than those obtained in H.H or V.H. samples. Nevertheless, the intensity of antibody response induced by two injections of H.L. was similar to that induced by H.H. with one injection. Therefore, the CHV vaccine purified by affinity chromatography was as efficient as RBS in stimulating high titers of specific antibodies in Asian sea bass at a dosage of 15 μg/g FBW (H.H.) with one injection.

The carrying capacity of different insertion sites
Since the sites of N-/C-termini and Ala220 of linker loop are suitable positions for his-tag insertion, we went a step further to study their carrying capacity. NHV and 220HV can carry 16 and 12 amino acids, respectively, while CHV accommodates 6 amino acids, meaning that these three sites can carry short foreign peptides. To validate whether they can accommodate large functional proteins, GFP was inserted into these three sites. We found that no matter whether GFP fused directly with CP or connected to CP with a flexible linker, (GGGGS)₃, the GFP-tagged CP on sites of N-terminus and Ala220 were unable to form VLP even when the fusion proteins were soluble. The same result was obtained when GFP fused directly to the CP C-terminus. However, when connected with the (GGGGS)₃ linker, C-terminal GFP-tagged CP is soluble and can assemble into GFP-tagged VLP (CGV). The particle shape of CGV was similar to that of RBS (Figure 7B). CGV presents the GFP on the outer surface of particles as revealed by immune-EM (Figure 7B). Furthermore, the functional GFP can be visualized during the ultracentrifugation purification process. An additional file shows all the results on CGV production (Additional file 8). Therefore, the sites of N-terminus and Ala220 can only accommodate short peptides about 12–16 amino acids long while the C-terminus can carry functional proteins as large as GFP.

Real-time observation of the entry process of CGV
Invasion assays of CGV were performed to find out whether CGV has the ability to invade culture cells, which means whether GFP can be carried into the cells via VLP as an application for viral vector. The entry process of CGV should be recorded in a real-time way by inverted fluorescent microscopy directly but not by indirect methods such as IFA. As shown in Figure 8, CGV not only can enter SB cells but can finish the entry process within 1.5 h, meaning that the entry speed and destination of CGV were similar to that of RBS. Because CGV lacks the cascade amplification of IFA, its overall fluorescent signals are weaker than Figure 4. Interestingly, the average fluorescent at 4 h post invasion (hpi) was weaker than those of 1–1.5 h. However, the GFP was detected with a strong fluorescent signal near the nuclei of anti-GFP antibody in IFA at this time point (Figure 8 IFA). These results probably suggest that the VLP structure of CGV was disassembled at 4 hpi but the GFP epitope was still detected by IFA. Consequently, CGV is suitable for viral in-cell traffic research, such as one-virus tracking or real-time virus entry study. Moreover, the C-terminus

---

**Figure 7** GFP tagged VLP production and characterization. A GFP insertion design and the additional amino acid sequences. NGCP represents the N-terminal GFP-tagged CP, 220GCP represents the Ala220 GFP-tagged CP, CGCP indicates the C-terminal GFP-tagged CP and (GGGGS)₃ represents the flexible linker. The black blocks represent CP and the rectangle frames indicate GFP. B Immuno-EM was performed to detect the GFP display status of CGV and CGV was immune-labeled with 5 nm gold particles using mouse anti-GFP or not as first antibody as indicated. The bar indicates 100 nm.

**Figure 8** Real-time observation of cell entry of CGV. Purified CGV was used to invade SB cells and photographed under fluorescent microscopy at the time indicated. IFA shows that the panel resulted from IFA using anti-GFP as the first antibody. The bar indicates 100 μm.
of CP is an excellent position for accommodating large functional proteins with outer surface displaying.

**Discussion**

The accumulation of high-resolution viral structural information has facilitated the ability to modify VLP deliberately. Consequently, VLP can essentially function as molecular scaffolds for presenting foreign antigens by genetic insertion [32]. Both double- and single-stranded DNA and RNA viruses, including 14 families of viruses have been successfully generated by the chimeric VLP [33, 34]. Studies of chimeric VLP in betanodavirus are non-existent and the structural information is maintained at approximately 7.5 Å [35] and 23 Å resolution [36] according to the VLP of dragon grouper nervous necrosis virus and malabaricus grouper nervous necrosis virus. In this study, we report the 3D structures of OGNNV at 3.9 Å resolution determined by cryo-EM and single-particle reconstruction, and define the capsid protein containing N, S and P domains and a linker loop as the linkage between the S and P domains. Structures of the Flock House Virus (FHV) which belong to alphanodavirus have been studied in depth [37]. The crystal structure of nematode-infecting virus which is also related to the *Nodaviridae* was recently reported [38]. Compared with the reported structures of nodavirus, the canonical jelly-roll structure of the S domain is the most common. When Dali [39] is used to analyses the homologs of the S domain, the OGNNV S domain is best aligned to the nematode-infecting virus (Z score = 10.1) [38], while compared to that of FHV, the Z score is only 4.9. Interestingly, the S domain has a higher similarity to some plant virus shell proteins compared to that of the FHV which is thought to be the representative virus of *Alphanodavirus*. The Z score for the comparison to carnation mottle virus [40] and maize chlorotic mottle virus [41] is 8.0 and 5.6, respectively. In the reported alphanodavirus, there is no obvious protrusion. The P domain of OGNNV composing a trimeric protrusion was similar to that of the nematode-infection virus. Although the reported betanodavirus structure is only in low resolution, it also showed that there are trimeric surface protrusions [36].

The high resolution structure of the capsid allows us to identify the structure details and the putative important sites for VLP modification. Based on the structural results, the N-terminals are located inside the capsid shell, and it can be a negative site for outer surface presentation. Ala220 is located at the tip of the capsid surface and it is located at the linker which connects the capsid shell and the protrusions together. Therefore, we should pay more attention to Ala220. Both C-terminals of the beta and gamma subunits are packaged inside the capsid shell in the mature alphanodavirus [42], while in the betanodavirus, all the C-terminals of the CP stick out from the capsid shell. Although at the current state, we cannot tell the detailed locations of them in the protrusions, we can see that the protrusions are at the most outside of the RBS and all the C-termini are definitely packaged in the protrusions. Therefore, we can set N-/C-termini, Ala220 of the linker loop and several points among the protrusions as candidates that could be target sites for potential vaccine design. In the insertion study, different HCP were screened by VLP production, showing that the positions 0, 220, 292 and 338 can carry foreign peptides to assemble into VLP. Our results also show that the C-terminus and Ala220 (the linker loop) of CP are valuable sites for accommodating foreign peptides on the exterior surface, while the N-terminus accepts peptides in the interior of VLP, which is consistent with the structural results. Furthermore, the N-terminus and the linker loop can only carry short peptides while the C-terminus can accommodate large functional proteins such as GFP with a flexible linker. Cell invasion assays proved that NHV, 220HV, CHV and CGV maintain their cell tropism (entry receptor[s]) and entry ability (endocytosis pathway) as native VLP. Moreover, the application studies of tagged VLP show the potential use of C-terminal insertion. Addition of the His-tag to the C-terminal of CP does not alter the structure or immunogenicity of VLP, as proven by fish immunization studies, showing that the strategy of adding small tags to facilitate purification is feasible and practical in VLP vaccine development. It is noteworthy that equal dose of VLP induced relatively lower antibody titers in sea bass than in groupers [12], suggesting the lower VLP susceptibility of sea bass. CGV, the GFP carrying VLP, shows the potential application of VLP vector development. To the best of our knowledge, this work is the first study to describe the exogenous-tagged VLP of betanodavirus.

Many studies have focused on the modification of the structure protein of either recombinant viruses or VLP to achieve basic structural and application research. For example, the core particle of the hepatitis B virus, namely HBC, has become one of the most popular carriers for the presentation of foreign peptides [43]. The foreign peptides are inserted either into the N-/C-termini of HBc or the immunodominant loop region located at the tip of the surface “spikes” on HBc particles by genetic fusion [44, 45], or linked to native HBc by chemical coupling [46], or attached to the fusion binding tag on HBc by protein–protein interaction [47]. FHV was also utilized as a display system to present the receptor von Willebrand A domain which can effectively bind the protective antigen of *Bacillus anthracis* at the surface of FHV VLP. The recombinant FHV VLP can neutralize the anthrax intoxication in vitro and in vivo, exhibiting the display potency.
of nodavirus VLP [48]. There is no modification study on epitope addition or chimeric VLP in betanodavirus, except for published reports about point mutation [49, 50] or terminal deletion [51]. We found that the C-terminus of OGNNV CP can accommodate the His-tag and functional GFP without changing the VLP structure, suggesting the possible application of the viral vector as developed in alphanodavirus.

Betanodaviruses infect many marine fish species [2], suggesting their strong infectivity to a wide range of hosts. OGNNV VLP can successfully enter several types of fish and mammalian cell lines determined by cell entry assays, probably via a clathrin-dependent endocytosis pathway (unpublished data). Thus, betanodavirus VLP is an easily delivered viral vector with the ability to enter different hosts, especially mammals. In respect of inducing the host’s immune response, several types of VLP have been proven to activate the innate immune system [52] and cellular immune system by pathogen-associated molecular pattern motifs [32]. VLP serve not only as scaffolds for presenting antigens derived from other pathogens in a suitable repetitive configuration but also as adjuvants to boost the immune response [34, 53]. The narrow host range (marine fish) of betanodavirus, in particular, may stand a good chance of activating the mammalian immune system quickly and vigorously because of limited contact between betanodaviruses and mammals. Consequently, betanodavirus VLP are perfect “self-adjuvanting” immunogen delivery platforms for foreign peptides. On the contrary, some researchers have added functional foreign peptides to change cell tropism 17 by reducing natural virus–cell interactions and conferring the ability to bind to new target receptors, resulting in a new strategy for developing novel delivery vehicles.

NVH, the VLP fused with His-tag on the N-terminus, is a useful type of viral vector that differs from 220HV and CHV by its enclosed N-terminal His-tag. The key advantage of the N-terminal fusion vessel is that the fused short peptides can be protected by the VLP shield, which makes the peptides take effect in cells precisely when the VLP are lysed or disassembled without the influences of the VLP entry process. The His-tags of NHV were proved to be non-detectable by anti-His antibodies during immune-EM and IFA in cell entry assay when NHV presents as fine structural particles. Therefore, the structural completeness of NHV can be evaluated by anti-His antibodies against the His-tag marker. Thus, the timing and position of lytic virions can be revealed in a time-resolved manner. This strategy can provide more detailed information on intracellular traffic of betanodaviruses after endocytosis and NHV is a good tool for studying the betanodavirus endocytosis. A more sophisticated but similar strategy to elucidate the endocytosis details has been applied to HIV-1 studies. Time-resolved single-virus imaging and a virus population-based fusion assay were performed to delineate the cellular entry sites of HIV-1. The results revealed that complete HIV-1 fusion occurs in endosomal compartments but not at the plasma membrane of epithelial and lymphoid cells [54]. In summary, VLP of the betanodavirus, OGNNV, were studied structurally, the key sites for accommodating foreign peptides were investigated and the applications of easy purification and real-time viral tracking were performed, providing information for potential biotechnological applications.
Abbreviations
OGNNV: Orange-spotted grouper nervous necrosis virus; CP: Capsid protein; VLP: Virus-like particle; 3D: Three-dimensional; His: 6x histidine; HCP: His-tagged capsid protein; HV: His-tagged virus-like particle; NMV: N-terminal His-tagged virus-like particle; CHV: C-terminal His-tagged virus-like particle; CGV: C-terminal GFP-tagged virus-like particle; EM: Electron microscopy; RBS: OGGNNV; GFP: Green fluorescent protein; SB cell: Asian sea bass fibroblast cell; BSA: Bovine serum albumin; IF: Indirect immunofluorescence assays; N–NTA: Nickel-nitrilotriacetic acid; FBW: Fish body weight; hpi: Hour post infection; FHV: Flock house virus.

Competing interests
The authors declare that they have no competing interests.

Author details
1 State Key Laboratory of Biocontrol, MOE Key Laboratory of Aquatic Product Safety, Institute of Aquatic Economic Animals and Guangdong Province Key Laboratory for Aquatic Economic Animals, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China. 2 Department of Nephrology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 518080, China. 3 School of Marine Sciences, Sun Yat-sen University, Guangzhou 510275, China.

Authors’ contributions
JX designed the study, carried out most of the experiments and drafted the manuscript. KL and YG performed all the Cryo-EM data collections and the structural analysis. RH, YL, SY and GZ participated in the molecular and immunological studies. QZ and JH supervised the work and edited the final version of this manuscript. All authors read and approved the final version of the manuscript.

Acknowledgements
This work was supported by the National Natural Science Foundation of China (No. 31100533), the National Key Technologies R&D Program (No. 2011BAD17B02, 2011BAD13B11, 2007BAD29B0S), the Science and Technology Projects of Guangdong Province (No. 2012A020800006, 2011A020102002), the Fundamental Research Funds for the Central Universities of China (No. 31610709, 13phy16), the State Scholarship Fund of the China Scholarship Council (CSC) (No. 2008109931). We thank Dr Gang Ji and Dr Xiaojun Huang in the Institute of Biophysics (IBP), Chinese Academy of Sciences for their technical help in the facilities usage.

Received: 16 July 2015 Accepted: 21 December 2015

Published online: 11 January 2016

References
1. King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ (2011) Virus taxonomy: classification and nomenclature of viruses. Ninth report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, London, San Diego
2. Nakai T, Mori K, Sugaya T, Nishioka T, Mushiake K, Yamashita H (2009) Current knowledge on viral nervous necrosis (VNN) and its causative betanodaviruses. Isr J Aquacult-Bamid 61:198–207
3. Munday B, Kwang J, Moody N (2002) Betanodavirus infections of teleost fish: a review. J Fish Dis 25:6
4. Husgaro S, Grotmol S, Hjeltnes BK, Rodseth OM, Biering E (2001) Immune response to a recombinant capsid protein of striped jack nervous necrosis virus (SNNV) in turbot Scophthalmus maximus and Atlantic halibut Hippoglossus hippoglossus, and evaluation of a vaccine against SNNV. Dis Aquat Organ 45:33–44
5. Yuasa K, Nishihara I, Roza D, Mori K, Kataoka M, Nakai T (2002) Immune response of humpback grouper, Crematogaster altivelis (Valenciennes) injected with the recombinant coat protein of betanodavirus. J Fish Dis 25:53–56
6. Coeurdacier JL, Laporte F, Pepin JF (2003) Preliminary approach to find synthetic peptides from nodavirus capsid potentially protective against sea bass viral encephalopathy and retinopathy. Fish Shellfish Immunol 14:435–447
7. Yamashita H, Mori K, Kuroda A, Nakai T (2009) Neutralizing antibody levels for protection against betanodavirus infection in sevenband grouper, Epinephelus septemfasciatus (Thunberg), immunized with an inactivated betanodavirus vaccine. J Fish Dis 32:767–775
8. Yamashita H, Mori K, Nakai T (2009) Protection conferred against viral nervous necrosis by simultaneous inoculation of aquabacteria and inactivated betanodavirus in the sevenband grouper, Epinephelus septemfuscias (Thunberg). J Fish Dis 32:201–210
9. Pakingking R Jr, Seron R, dela Pena L, Mori K, Yamashita H, Nakai T (2009) Immune responses of Asian sea bass, Lates calcarifer, against an inactivated betanodavirus vaccine. J Fish Dis 32:457–463
10. Thirey R, Cozien J, Cabon J, Lamour F, Baud M, Schneemann A (2006) Induction of a protective immune response against viral nervous necrosis in the European sea bass Dicentrarchus labrax by using betanodavirus-like particles. J Virol 80:10201–10207
11. Liu WT, Hsu CH, Chang CY, Chen HH, Lin CS (2006) Immune response against group B nervous virus by vaccination of virus-like particles. Vaccine 24:6282–6287
12. Lai YJ, Yin BL, Xu Y, Huang LJ, Huang RQ, Zhang Y, Kwang J, He JG, Xie JF (2014) Immune responses of orange-spotted grouper, Epinephelus coioides, against virus-like particles of betanodavirus produced in Escherichia coli. Vet Immunol Immunopathol 157:81–96
13. Valley-Omar Z, Meyers AE, Shephard EC, Williamson AL, Rybicki EP (2011) Abrogation of contaminating RNA activity in HIV-1 gag VLPs. J Virol 85:8622–8632
14. Giord C, Chazal N, Brutl T (2011) Cellular kinases incorporated into HIV-1 particles: passive or active passagers? Retrovirology 8:71
15. Garcea RL, Gissmann L (2004) Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 15:513–517
16. Roy P, Noad R (2008) Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccin 4:5–12
17. Takahashi R, Kanasashi S, Inoue T, Enomoto T, Kawano M, Tsukamoto H, Takeshita I, Ochiya T, Kataoka K, Yamaguchi Y, Handa H (2008) Presentation of functional foreign peptides on the surface of SV40 virus-like particles. J Biotechnol 135:383–392
18. Maree JJ, van der Walt E, Tiedt FAC, Hanlizk TN, Appel M (2006) Surface display of an internal His-tag on virus-like particles of Nudaurelia copepsis virus (NwV) produced in a baculovirus expression system. J Virol Methods 136:283–288
19. Yu XK, Ge P, Jiang JS, Atanasov I, Zhou ZH (2011) Atomic model of CPV reveals the mechanism used by this single-shelled virus to economically carry out functions conserved in multishelled reoviruses. Structure 19:652–661
20. Bartesaghi A, Merk A, Barnerjee S, Matthies D, Wu X, Milne JL, Subramanian S (2015) 2.2 Å resolution cryo-EM structure of beta-galactosidase in complex with a cell-permeant inhibitor. Science 348:1147–1151
21. Tang G, Peng L, Baldwin PR, Mann DS, Jiang W, Reeves J, Ludkte SJ (2007) EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol 157:38–46
22. Ludtke SJ, Baldwin PR, Chiu W (1999) EMAN: semi-automated software for high-resolution single-particle reconstructions. J Struct Biol 128:82–97
23. Guo F, Jiang W (2014) Single particle cryo-electron microscopy and 3-D reconstruction of viruses. Methods Mol Biol 1117:401–443
24. Scheres SHW, Chen SX (2012) Prevention of overfitting in cryo-EM structural determination. Nat Methods 9:853–854
25. Swind-Kruze L, Brown CS (2005) Remap: automated representation of macromolecular interfaces as two-dimensional networks. Bioinformatics 21:3327–3328
26. Petersen EF, Goodard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612
27. Kelley LA, Mezulis S, Yates CM, Wiss MN, Sternberg MJ (2015) The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 10:845–854
28. Zhang Q, Dai X, Cong Y, Zhang J, Chen DH, Dougherty MT, Wang J, Ludtte SJ, Schmid MF, Chiu W (2013) Cryo-EM structure of a molluscan hemocyanin suggests its allosteric mechanism. Structure 21:604–613
29. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–2132
30. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read JD, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH
31. Fenner BJ, Thiagarajan R, Chua HK, Kwang J (2006) Betanodavirus B2 is an RNA interference antagonist that facilitates intracellular viral RNA accumulation. J Virol 80:85–94
32. Crisci E, Barcena J, Montoya M (2012) Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 148:211–225
33. Chackerian B (2007) Virus-like particles-flexible platforms for vaccine development. Expert Rev Vaccines 6:381–390
34. Grgacic EV, Anderson DA (2006) Virus-like particles: passport to immune recognition. Methods 40:60–65
35. Luo YC, Wang CH, Liu W, Tu MH, Chang WH, Lin CS (2014) Insight into the three-dimensional structure of maize chlorotic mottle virus revealed by Cryo-EM single particle analysis. Virology 485:171–178
36. Schneemann A, Marshall D (1998) Specific encapsidation of nodavirus RNAs is mediated through the C terminus of capsid precursor protein alpha. J Virol 72:8738–8746
37. Banerjee M, Speir JA, Kwan MH, Huang R, Aryanpur PP, Bothner B, John-son JE (2010) Structure and function of a genetically engineered mimic of a nonenveloped virus entry intermediate. J Virol 84:4737–4746
38. Lu MW, Lin CS (2003) Involvement of the terminus of grouper betanoda-virus in the infection. J Virol 76:6370–6375
39. Holm L, Rosenstrom P (2010) DALI server: conservation mapping in 3D. Nucleic Acids Res 38:W545–W549
40. Morgunova E, Dauter Z, Fry E, Stuart DI, Stel’mashchuk V, Mikhailov AM, Wilson KS, Vainshtein BK (1994) The atomic structure of Carnation Mottle Virus capsid protein. FEBS Lett 338:267–271
41. Wang CV, Zhang QF, Gao YZ, Zhou XP, Ji G, Huang XJ, Hong J, Zhang CX (2015) Insight into the three-dimensional structure of maize chlorotic mottle virus revealed by Cryo-EM single particle analysis. Virology 485:171–178
42. Schneemann A (2007) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213–221
43. Pumpens P, Gens E (2001) HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44:98–114
44. Kratz PA, Bottcher B, Nassal M (1999) Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci U S A 96:1915–1920
45. Skamel C, Ploss M, Bottcher B, Stehle T, Wallich R, Simon MM, Nassal M (2006) Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection. J Biol Chem 281:17474–17481
46. Jegerlehrer A, Tissot A, Lechner F, Seebel P, Erdmann I, Kundig T, Bachi T, Storm T, Jennings G, Pumpens P, Renner WA, Bachmann MF (2002) A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20:3104–3112
47. Blokhina EA, Kuprianov VV, Stepanova LA, Tsyalovalo LM, Kiselev OI, Ravin NV, Skryabin KG (2013) A molecular assembly system for presentation of antigens on the surface of HBC virus-like particles. Virology 435:293–300
48. Manayani DJ, Thomas D, Dryden KA, Reddy V, Siladi ME, Marleit JM, Rainey GJA, Pique ME, Scobie HM, Yeager M, Young JAT, Manchester M, Schneemann A (2007) A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog 3:1422–1431
49. Wu YM, Tsai CH, Wang CH, Liu W, Chang WH, Lin CS (2008) Role of the DxxDxD motif in the assembly and stability of betanodavirus particles. Arch Virol 153:1633–1642
50. Wang CH, Tsai CH, Wu YM, Luo YC, Tu MH, Chang WH, Cheng RH, Lin CS (2010) Roles of cysteines Cys115 and Cys201 in the assembly and thermostability of grouper betanodavirus particles. Virus Genes 41:73–80
51. Lu MW, Lin CS (2003) Involvement of the terminus of group B betanoda-virus capsid protein in virus-like particle assembly. Arch Virol 148:345–355
52. Plummer EM, Manchester M (2011) Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanobiototechnol 3:174–196
53. Ludwig C, Wagner R (2007) Virus-like particles-universal molecular tool-boxes. Curr Opin Biotechnol 18:537–545
54. Miyachi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:433–444

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit